Immuneering (IMRX) Capital Expenditures (2020 - 2026)
Immuneering (IMRX) posted quarterly Capital Expenditures of $79930.0 for Q1 2026, up 793.57% year-over-year from $8945.0 in Q1 2025, and down 35.49% quarter-over-quarter from $123910.0 in Q4 2025.
Powered by 
Analysis
Immuneering (IMRX) Capital Expenditures (2020 - 2026) Analysis & Trends
Immuneering's Capital Expenditures history runs 7 years deep, the most recent figure standing at $79930.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 793.57% year-over-year to $79930.0; the TTM figure through Mar 2026 stood at $213211.0 (up 278.42% YoY), while the FY2025 annual figure was $142226.0, up 67.57% from the prior year.
- Capital Expenditures for Q1 2026 stood at $79930.0, down from $123910.0 in the prior quarter.
- The five-year high for Capital Expenditures was $393134.0 in Q3 2022, with the low at $2116.0 in Q2 2025.
- The 5-year median for Capital Expenditures is $57149.0 (2023), against an average of $81897.6.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures soared 3364.96% in 2022, then sank 94.53% in 2024.
- Immuneering's Capital Expenditures stood at $69302.0 in 2022, then soared by 146.63% to $170918.0 in 2023, then tumbled by 94.53% to $9356.0 in 2024, then jumped by 1224.39% to $123910.0 in 2025, then tumbled by 35.49% to $79930.0 in 2026.
- Business Quant data shows IMRX's Capital Expenditures at $79930.0 in Q1 2026, $123910.0 in Q4 2025, and $7255.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Immuneering | 313.13 Mn | 313.13 Mn | - | 27,367.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27,367.00 |
| Mar 31, 2026 | 79,930.00 |
| Dec 31, 2025 | 123,910.00 |
| Sep 30, 2025 | 7,255.00 |
| Jun 30, 2025 | 2,116.00 |
| Mar 31, 2025 | 8,945.00 |
| Dec 31, 2024 | 9,356.00 |
| Sep 30, 2024 | 5,268.00 |
| Jun 30, 2024 | 32,773.00 |
| Mar 31, 2024 | 37,478.00 |
| Dec 31, 2023 | 170,918.00 |
| Sep 30, 2023 | 57,149.00 |
| Jun 30, 2023 | 86,686.00 |
| Mar 31, 2023 | 27,993.00 |
| Dec 31, 2022 | 69,302.00 |
| Sep 30, 2022 | 393,134.00 |
| Jun 30, 2022 | 164,997.00 |
| Mar 31, 2022 | 115,050.00 |
| Dec 31, 2021 | 13,052.00 |
| Sep 30, 2021 | 11,346.00 |